Education
About Us
Working with TipRanks
Follow Us
Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.69
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.69
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.49 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€705.63M
Enterprise Value€910.85M
Total Cash (Recent Filing)€95.70M
Total Debt (Recent Filing)€397.10M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 28, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding967,343,750
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.09Price Target Upside57.36% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.81M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthSustained and growing free cash flow provides durable financial flexibility: it funds inventory and capex, enables continued debt reduction and dividends, and cushions the business through retail cycles. Strong cash conversion also supports reinvestment in DTC and brand initiatives over multiple years.
High Gross MarginA near-65% gross margin reflects meaningful pricing power and favorable product economics from premium footwear and mix. This structural margin buffer helps absorb retail cost pressures and supports profitability recovery as full-price mix and cost discipline improve, sustaining margins over upcoming quarters.
Improving Revenue Quality (full-price DTC)A shift toward full-price DTC sales and more new full-price customers improves unit economics and reduces markdown dependency. This structural improvement in revenue quality supports higher gross profit per sale and more predictable margins and customer LTV versus promotional-driven volumes.
Bears Say
Declining Revenue And ProfitabilityMulti-year revenue decline and falling profitability undermine scale advantages and operating leverage. Persistent top-line weakness constrains reinvestment, weakens bargaining power with suppliers and retailers, and makes margin recovery and consistent returns more difficult over the medium term.
Sharp ROE DeteriorationA collapse in ROE signals the company is generating minimal returns on capital versus prior years. Restoring capital efficiency requires sustained profit recovery or asset optimization; until then, shareholder returns and ability to self-fund growth initiatives remain structurally constrained.
Tariff And Regional/product HeadwindsOngoing tariff costs and regional product challenges (EMEA DTC softness and boots/sandals underperformance) create structural margin pressure and uneven geographic performance. These persistent cost and assortment issues raise the hurdle for sustainable margin recovery across key markets.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.49 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €705.63M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 72 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -€0.01 earnings per share for the quarter, the consensus estimate of -€0.01 by €0.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.06.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,343,750 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -€0.01 in its last earnings report, expectations of -€0.01. Following the earnings report the stock price went up 0.564%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.09 (57.36% Upside)
€1.09 (57.36% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
1.23%
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.09
▲(57.36% Upside)
Technical Analysis
Options Prices
Currently, No data available
---